(MedPage Today) — In treatment‑experienced psychiatric patients receiving established pharmacotherapy, adjunctive L‑methylfolate (Deplin) was linked with significant reductions in overall symptom burden and improvements in executive function.
Trending
- BBC pundit identifies three major Manchester United problems that go beyond Michael Carrick
- Nvidia Launches Independent Investigation into CEO’s Alleged Affair with Suspected Chinese Spy
- CJ Carr Leads Notre Dame Into Perfect CFP Position After Revenge Upset of Miami
- L‑Methylfolate Adjunct Therapy Enhances Symptoms and Cognitive Function in Treated Psychiatric Patients
- ‘Avedon’ Review: Ron Howard’s Thrilling Documentary About Richard Avedon, the Great Photographer Who Turned Head-On Portraits Into an Art Form
- Devastating Sand Cliff Collapse Threatens Displaced Community in Gaza
- Native American Women Score Historic Wins in U.S. Midterm Elections
- Kimi Antonelli’s Spin and Car Instability Cost Brazil GP Victory, Despite Mercedes Securing Constructors’ Title
(MedPage Today) — In treatment‑experienced psychiatric patients receiving established pharmacotherapy, adjunctive L‑methylfolate (Deplin) was linked with significant reductions in overall symptom burden and improvements in executive function.